A Phase I Study of Gemcitabine Plus Irinotecan for Advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904)

被引：1

作者：

Kurata, Takayasu ^{[1
]}

Yamamoto, Nobuyuki ^{[1
]}

Komiya, Takefumi ^{[1
]}

Tsurutani, Junji ^{[1
]}

Miyazaki, Masaki ^{[1
]}

Tamura, Kenji ^{[1
]}

Takeda, Koji ^{[2
]}

Nakagawa, Kazuhiko ^{[1
]}

Fukuoka, Masahiro ^{[1
]}

机构：

[1] Kinki Univ, Sch Med, Dept Med Oncol, Osaka 5898511, Japan

[2] Osaka City Gen Hosp, Dept Clin Oncol, Osaka, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 40卷 / 10期

关键词：

combination Phase I study; maximum tolerated dose; gemcitabine; irinotecan; NSCLC; CELL LUNG-CANCER; CHEMOTHERAPY;

D O I：

10.1093/jjco/hyq079

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A combination Phase I study of gemcitabine and irinotecan in patients with previously untreated advanced non-small-cell lung cancer was conducted. Patients received gemcitabine and irinotecan on Days 1 and 8 every 3 weeks. A total of 11 patients were enrolled. Three of six patients who received the starting dose (gemcitabine, 800 mg/m(2); irinotecan, 80 mg/m(2)) experienced dose-limiting toxicities (Grade 4 neutropenia, Grade 3 elevation of transaminase and Grade 5 interstitial pneumonia). At the reduced dose level (gemcitabine, 800 mg/m(2); irinotecan, 60 mg/m(2)), all two assessable patients could not meet the administration criteria of Day 8 (one, Grade 2 elevation of transaminase; the other, Grade 1 diarrhea). No objective response was observed in eight evaluable patients. We could not determine the recommended dose of this combination because of intolerable toxicities and no efficacy. Therefore, it is difficult to forward this combination chemotherapy toward further studies.

引用

页码：992 / 994

页数：3

共 3 条

[1] A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane plus platinum-based regimens [J].

Kosmas, Christos ;

Tsavaris, Nicolas ;

Syrigos, Konstantinos ;

Koutras, Angelos ;

Tsakonas, George ;

Makatsoris, Thomas ;

Mylonakis, Nicolas ;

Karabelis, Athanasios ;

Stathopoulos, George P. ;

Kalofonos, Haralambos P. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (01) :51-59

[2] Phase I study of combination chemotherapy with gemcitabine and irinotecan for non-small cell lung cancer [J].

Nishio, M ;

Ohyanagi, F ;

Taguch, F ;

Matsuda, M ;

Sato, Y ;

Okumura, S ;

Nakagawa, K ;

Horai, T .

LUNG CANCER, 2005, 48 (01) :115-119

[3] Phase I study of irinotecan and gemcitabine in previously untreated, patients with advanced non-small cell lung cancer [J].

Takatani, Hiroshi ;

Soda, Hiroshi ;

Nakamura, Yoichi ;

Kinoshita, Akitoshi ;

Fukuda, Masaaki ;

Nagashima, Seiji ;

Fukuda, Minoru ;

Soejima, Yoshifumi ;

Nakano, Hirofumi ;

Oka, Mikio ;

Kohno, Shigeru .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (05) :353-357

← 1 →